On Monday, Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX), gained 12.27% to $15.46.
Celldex Therapeutics, presented new preclinical data on varlilumab, a fully human monoclonal agonist antibody that binds and activates CD27, a critical co-stimulatory molecule in the immune activation cascade. Results suggest that cancers may respond to CD27 immune modulation by independent mechanisms, such as immune co-stimulation and regulatory T cell (Treg) depletion. Varlilumab has the unique ability to act through both of these mechanisms. The new data were presented in a poster entitled “The mechanism of anti-tumor immunity induced by varlilumab, a CD27 agonist mAb, is model dependent” at the Society for the Immunotherapy of Cancer (SITC) Annual Meeting.
“Our data show that CD27 modulation through varlilumab results in immune activation and suppression of Treg activity, either of which can be independently responsible for a therapeutic effect, depending on the cancer model,” said Tibor Keler, Ph.D., Executive Vice President and Chief Scientific Officer of Celldex Therapeutics. “Because individual human cancers are also likely to have different sensitivities to these anti-tumor activities, varlilumab’s ability to act through both mechanisms provides the broadest potential for therapeutic benefit. Our collection of preclinical and clinical results to date support Celldex’s broad clinical development program across tumor types and in combinations with other anti-tumor agents.”
To better understand each mechanism separately, scientists engineered varlilumab to possess either strong co-stimulatory activity (varli-mG1) or strong Treg suppression activity (varli-mG2a) and analyzed their efficacy in several preclinical tumor models. The data indicated that potent co-stimulation activity was required for therapeutic activity in a BCL1 lymphoma model, whereas control of Tregs was required for activity in several other models, such as E.G7 thymoma, CT26 colorectal and colon 26. Importantly, varlilumab has a combination of immune co-stimulation and Treg depleting activity and demonstrated potent anti-tumor activity in all the models.
Celldex Therapeutics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes novel therapeutics for human health care in the United States. The companys lead drug candidates comprise rindopepimut (CDX-110), a targeted immunotherapeutic in a pivotal Phase III study for the treatment of front-line glioblastoma, in addition to in Phase II study for the treatment of recurrent glioblastoma; and Glembatumumab vedotin (CDX-011), a targeted antibody-drug conjugate in a randomized Phase IIb study for the treatment of triple negative breast cancer, in addition to in Phase II study for the treatment of metastatic melanoma.
Shares of Berkshire Hathaway Inc. (NYSE:BRK.B), declined -1.57% to $134.19, during its last trading session.
Berkshire’s operating results for the third quarter and first nine months of 2015 are summarized in the following paragraphs. However, we urge investors and reporters to read our 10-Q, which has been posted at www.berkshirehathaway.com. The limited information that follows in this press release is not adequate for making an informed investment judgment.
Earnings of Berkshire Hathaway Inc. and its merged auxiliaries for the third quarter and first nine months of 2015 and 2014 are summarized below. Earnings are stated on an after-tax basis. (Dollar amounts are in millions, except for per share amounts).
Berkshire Hathaway, Inc. is a publicly owned investment manager. Through its auxiliaries, the firm primarily engages in the insurance and reinsurance of property and casualty risks business. Berkshire Hathaway was founded in 1889 and is based in Omaha, Nebraska.
Finally, Shares of New York REIT Inc (NYSE:NYRT), ended its last trade with -4.14% loss, and closed at $11.12.
New York REIT, declared its financial and operating results for the third quarter ended September 30, 2015.
New York REIT, Inc. focuses on acquiring commercial real estate, in addition to acquiring properties or making other real estate investments that relate to office, retail, multi-family residential, industrial, and hotel property types located primarily in New York City. It intends to qualify as a real estate investment trust for the U.S. federal income tax purposes.